Work

Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial

Year: 2026
Type: conference-abstract
Language: English
Subfield: Cancer Research
Open Access status: closed
OpenAlex ID: W7129576123
Cites:
Cited by:
Related to: